Compare Crispr Therapeutics AG (CRSP) vs General Mills, Inc. (GIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs General Mills, Inc. — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while General Mills, Inc. trades at $32.29 (market cap $17.43B). The key difference: General Mills, Inc. is far larger — about 3.6× Crispr Therapeutics AG's market cap, and General Mills, Inc. pays a 7.49% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and General Mills, Inc. for 106 Days on average.
| CRSP | GIS | |
|---|---|---|
Market Cap | $4.88B | $17.43B |
Volume | 2,861,747 | 16,554,362 |
Sector | Health | Consumer Staples |
52-Week High | $74.92 | $49.36 |
52-Week Low | $44.34 | $31.67 |
Typical Hold Time | 77 Days | 106 Days |
Enterprise Value | $3.30B | $30.61B |
Dividend Yield | — | 7.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.39, up 1.99% on the day, but remains in a bearish technical trend. The company shows no revenue in 2025, with significant losses (net income margin -4,101.26%) and negative cash flow from operations. However, analyst sentiment is positive with a 57.9% buy rating and a $67.83 consensus price target, citing upcoming clinical data catalysts for its gene-editing therapies like CASGEVY and zugo-cel.
The outlook hinges on successful clinical execution and commercialization of its pipeline. Near-term catalysts include data readouts in autoimmune diseases, but high cash burn, intense competition, and regulatory risks pose substantial challenges. The stock offers high-risk, high-reward potential for investors betting on gene-editing breakthroughs.
General Mills (GIS) trades at $32.59, up 2.58% today, but faces fundamental challenges with negative net income margin (-4.89%) and ROE (-10.55%) for 2026. The stock shows bearish technical signals with mixed earnings performance - missing Q4 2025 estimates but beating Q2 2026. Recent CEO transition to Dana McNabb and a $3 billion cost-saving initiative aim to stabilize operations amid declining revenue trends from $19.5B (2025) to $18.3B (2026).
The stock presents a high-yield opportunity with a $0.61 dividend, but significant risks include persistent margin pressure and rising debt-to-asset ratio (45% in 2025). Analyst consensus is cautious with 61% hold ratings, though the $36 price target suggests 10% upside. Investors should weigh the dividend stability against fundamental deterioration and leadership transition execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →
